The FDA expanded the approved indications for pembrolizumab (Keytruda, Merck), granting the checkpoint inhibitor accelerated approval for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib (Nexavar, Bayer).
"Hepatocellular carcinoma is the most common type of liver cancer in adults, and while we have seen recent therapeutic advancements, there are still limited treatment options for advanced recurrent disease,” said Andrew X. Zhu, MD,NOVEMBER 26, 2018